Replies to post #110944 on Biotech Values

[ilpapa]

the FDA did not require "sameness" or complete characterization in approving MNTA's generic:


That can only be interpreted as favorable to TEVA's early approval chances and may explain why MNTA trades like the sword of Damocles was hanging over its head. When the sword falls, the negative effect may be limited.